Cargando…
The dietary supplement Cyplexinol(®) alleviates joint pain in men and women
BACKGROUND AND AIM: Joint pain afflicts millions of adults worldwide. The effect of a bone morphogenetic protein complex on joint pain is assessed in this study. METHODS: We compared the impact of a dietary supplement protein complex (Cyplexinol(®)) and placebo in 18 men and women (aged 43 ± 10 year...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Whioce Publishing Pte. Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339409/ https://www.ncbi.nlm.nih.gov/pubmed/37457546 |
_version_ | 1785071839046795264 |
---|---|
author | Pence, Jacquelyn Stockton, Michelle Bloomer, Richard J. |
author_facet | Pence, Jacquelyn Stockton, Michelle Bloomer, Richard J. |
author_sort | Pence, Jacquelyn |
collection | PubMed |
description | BACKGROUND AND AIM: Joint pain afflicts millions of adults worldwide. The effect of a bone morphogenetic protein complex on joint pain is assessed in this study. METHODS: We compared the impact of a dietary supplement protein complex (Cyplexinol(®)) and placebo in 18 men and women (aged 43 ± 10 years) with self-reported joint pain. Subjects were randomly assigned to each condition, consumed twice daily for 14 days (900 mg/day). Subjects completed questionnaires (e.g., Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subjective pain using a visual analog scale [VAS]) at the start and end of each treatment phase. Blood samples were analyzed for bone morphogenic protein (BMP), alkaline phosphatase, and cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-10, IL-1β, and TGF-β). Blood was also collected on days 1 and 15 to determine the acute impact of treatment on these measures. RESULTS: Pain and discomfort scores improved (P ≤ 0.05) for subjects following use of Cyplexinol(®) but not placebo. Improvements were noted for WOMAC pain (P = 0.05), stiffness (P = 0.039), and total pain (P = 0.026), as well as VAS pain (P = 0.015), recreational activity interference (P = 0.023), mood interference (P = 0.012), and total pain (P = 0.024). A trend was noted for WOMAC physical function (P = 0.052). An approximate 50% increase in BMP5 was noted following Cyplexinol(®) (P = 0.01), with a similar increase noted for placebo (P = 0.022). A near doubling in TGF-β (P = 0.001) was noted for Cyplexinol(®). No other changes of significance were noted across time, nor were any differences noted in cytokines following acute intake of the conditions (P > 0.05). CONCLUSIONS: Cyplexinol(®) can alleviate joint pain in middle-aged men and women, while elevating BMP5 and TGF-β. Cyplexinol(®) does not influence cytokines, at least within a short 2-week supplementation period or within the 2-h post-ingestion period. RELEVANCE FOR PATIENTS: Individuals suffering with joint pain in the knee and/or hip may benefit from daily use of Cyplexinol(®), as we observed decreased pain and stiffness following treatment. |
format | Online Article Text |
id | pubmed-10339409 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Whioce Publishing Pte. Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103394092023-07-14 The dietary supplement Cyplexinol(®) alleviates joint pain in men and women Pence, Jacquelyn Stockton, Michelle Bloomer, Richard J. J Clin Transl Res Original Article BACKGROUND AND AIM: Joint pain afflicts millions of adults worldwide. The effect of a bone morphogenetic protein complex on joint pain is assessed in this study. METHODS: We compared the impact of a dietary supplement protein complex (Cyplexinol(®)) and placebo in 18 men and women (aged 43 ± 10 years) with self-reported joint pain. Subjects were randomly assigned to each condition, consumed twice daily for 14 days (900 mg/day). Subjects completed questionnaires (e.g., Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subjective pain using a visual analog scale [VAS]) at the start and end of each treatment phase. Blood samples were analyzed for bone morphogenic protein (BMP), alkaline phosphatase, and cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-10, IL-1β, and TGF-β). Blood was also collected on days 1 and 15 to determine the acute impact of treatment on these measures. RESULTS: Pain and discomfort scores improved (P ≤ 0.05) for subjects following use of Cyplexinol(®) but not placebo. Improvements were noted for WOMAC pain (P = 0.05), stiffness (P = 0.039), and total pain (P = 0.026), as well as VAS pain (P = 0.015), recreational activity interference (P = 0.023), mood interference (P = 0.012), and total pain (P = 0.024). A trend was noted for WOMAC physical function (P = 0.052). An approximate 50% increase in BMP5 was noted following Cyplexinol(®) (P = 0.01), with a similar increase noted for placebo (P = 0.022). A near doubling in TGF-β (P = 0.001) was noted for Cyplexinol(®). No other changes of significance were noted across time, nor were any differences noted in cytokines following acute intake of the conditions (P > 0.05). CONCLUSIONS: Cyplexinol(®) can alleviate joint pain in middle-aged men and women, while elevating BMP5 and TGF-β. Cyplexinol(®) does not influence cytokines, at least within a short 2-week supplementation period or within the 2-h post-ingestion period. RELEVANCE FOR PATIENTS: Individuals suffering with joint pain in the knee and/or hip may benefit from daily use of Cyplexinol(®), as we observed decreased pain and stiffness following treatment. Whioce Publishing Pte. Ltd. 2023-04-26 /pmc/articles/PMC10339409/ /pubmed/37457546 Text en Copyright: © 2023 Author(s). https://creativecommons.org/licenses/by-nc/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution-Noncommercial License, permitting all noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Pence, Jacquelyn Stockton, Michelle Bloomer, Richard J. The dietary supplement Cyplexinol(®) alleviates joint pain in men and women |
title | The dietary supplement Cyplexinol(®) alleviates joint pain in men and women |
title_full | The dietary supplement Cyplexinol(®) alleviates joint pain in men and women |
title_fullStr | The dietary supplement Cyplexinol(®) alleviates joint pain in men and women |
title_full_unstemmed | The dietary supplement Cyplexinol(®) alleviates joint pain in men and women |
title_short | The dietary supplement Cyplexinol(®) alleviates joint pain in men and women |
title_sort | dietary supplement cyplexinol(®) alleviates joint pain in men and women |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339409/ https://www.ncbi.nlm.nih.gov/pubmed/37457546 |
work_keys_str_mv | AT pencejacquelyn thedietarysupplementcyplexinolalleviatesjointpaininmenandwomen AT stocktonmichelle thedietarysupplementcyplexinolalleviatesjointpaininmenandwomen AT bloomerrichardj thedietarysupplementcyplexinolalleviatesjointpaininmenandwomen AT pencejacquelyn dietarysupplementcyplexinolalleviatesjointpaininmenandwomen AT stocktonmichelle dietarysupplementcyplexinolalleviatesjointpaininmenandwomen AT bloomerrichardj dietarysupplementcyplexinolalleviatesjointpaininmenandwomen |